Genocea Biosciences
Nov 9, 2016

Genocea to Present at Two Upcoming November Conferences

CAMBRIDGE, Mass., Nov. 09, 2016 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that management will present a company overview at two upcoming investor conferences in November:

A live webcast of these presentations can be accessed by visiting the "Events and Presentations" tab of the investor relations section of the Genocea website at A replay of the webcasts will be archived for 30 days following the presentation.

About Genocea Biosciences Inc.
Genocea is harnessing the power of T cell immunity to develop life-changing vaccines and immunotherapies. T cells are increasingly recognized as a critical element of protective immune responses to a wide range of diseases, but traditional discovery methods have proven unable to identify the targets of such protective immunity. Using ATLAS, its proprietary technology platform, Genocea identifies these targets to potentially enable the rapid development of medicines to address critical patient needs. Genocea's pipeline of novel clinical stage T cell-enabled product candidates includes GEN-003 for genital herpes, GEN-004 for the prevention of infection by all serotypes of pneumococcus (development suspended), and earlier-stage investments in cancer immunotherapy. Genocea also has earlier stage research programs in chlamydia, genital herpes and malaria which were paused in the fourth quarter of 2016. For more information, please visit the company's website at

For media:

Liz Bryan

Spectrum Science Communications, Inc.

O: 202-955-6222

For investors:

Jonathan Poole

Genocea Biosciences, Inc.

O: 617-876-8191

Primary Logo

Source: Genocea Biosciences

News Provided by Acquire Media